Early Drug Resistance Mutations Testing and Individualized Antiretroviral Therapy in HIV/AIDS Research

Strategic Insights -

In a landmark study conducted at the Mildmay-Uganda Hospital from 2018 to 2023, researchers analyzed data from 235 people living with HIV (PLHIV) and found that early drug resistance mutations testing and individualized antiretroviral therapy (ART) can significantly improve HIV treatment outcomes. The study, led by Collins Ankunda and colleagues, demonstrated the importance of early DRM testing and tailored ART, particularly as newer ART options emerge.

Key Takeaways:

  • The study retrospectively reviewed medical records of 235 PLHIV who underwent HIV drug resistance testing at the Mildmay-Uganda Hospital from 2018 to 2023.
  • The research demonstrated a high prevalence of drug resistance mutations (DRMs) among PLHIV in Uganda, highlighting the need for early DRM testing and individualized ART.
  • The study found a significant association between DRM prevalence and time to virological failure, with PLHIV with DRMs experiencing a median time to virological failure of 24.1 months, compared to 36.5 months for those without DRMs.
  • Collins Ankunda and colleagues emphasized the importance of early DRM testing, stating, "Findings support early DRM testing and individualized ART, especially as newer ART options emerge."
  • The study's findings have significant implications for HIV treatment outcomes in resource-limited settings, where DRMs can pose major challenges to ART effectiveness.

Statistics:

  • The study analyzed data from 235 PLHIV, representing 100% of the Mildmay-Uganda Hospital's HIV drug resistance testing sample from 2018 to 2023.
  • The research found a significant association between DRM prevalence and time to virological failure, with a hazard ratio of 2.14 (95% CI: 1.23-3.73).
  • The median time to virological failure among PLHIV with DRMs was 24.1 months (95% CI: 18.2-31.5), compared to 36.5 months (95% CI: 28.5-44.8) for those without DRMs.

Sources:

  • Ankunda, C., et al. (2025). Prevalence of drug resistance mutations and their association with time to virological failure in people living with HIV in Uganda. BMC Infectious Diseases, 25(1), 1241.
  • BioMed Central (2025). BMC Infectious Diseases. Volume 25, Issue 1.